Analysis of treatment in childhood leukaemia. II. Timing and the toxicity of combined 6-mercaptopurine and methotrexate maintenance therapy.

The first and second Medical Research Council UKALL trials have shown that alteration in the timing of methotrexate and 6-mercaptopurine maintenance therapy for the treatment of acute lymphoblastic leukaemia can markedly change drug induced toxicity. Maintenance chemotherapy in both trials used a similar total dosage of these drugs but the timing of their administration was different in the two schedules.

RCT Entities:   Population Interventions Outcomes